Genous™ endothelial progenitor cell-capturing stent system: a novel stent technology

References

• Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation108(7), 788–794 (2003).
   PubMed Web of Science ®Google Scholar
• Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the ENDEAVOR zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol.55(1), 1–18 (2007).
   PubMedGoogle Scholar
• Grube E, Silber S, Hauptmann KE et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation107(1), 38–42 (2003).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.346(23), 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349(14), 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA299(16), 1903–1913 (2008).
   PubMed Web of Science ®Google Scholar
• Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J.27(2), 166–170 (2006).
   PubMed Web of Science ®Google Scholar
• Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol.46(2), 231–236 (2005).
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents. importance of delayed healing. Arterioscler. Thromb. Vasc. Biol.27(7), 1500–1510 (2007).
   PubMed Web of Science ®Google Scholar
• Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation115(18), 2435–2441 (2007).
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA293(17), 2126–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol.48(1), 193–202 (2006).
   PubMed Web of Science ®Google Scholar
• Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll. Cardiol.45(12), 2088–2092 (2005).
   PubMed Web of Science ®Google Scholar
• Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med.356(10), 998–1008 (2007).
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science275(5302), 964–967 (1997).
   PubMed Web of Science ®Google Scholar
• Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res.85(3), 221–228 (1999).
   PubMed Web of Science ®Google Scholar
• Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med.348(7), 593–600 (2003).
   PubMed Web of Science ®Google Scholar
• Kawamoto A, Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter. Cardiovasc. Interv.70(4), 477–484 (2007).
   PubMed Web of Science ®Google Scholar
• Schmidt-Lucke C, Rossig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation111(22), 2981–2987 (2005).
   PubMed Web of Science ®Google Scholar
• Young PP, Vaughan DE, Hatzopoulos AK. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog. Cardiovasc. Dis.49(6), 421–429 (2007).
   PubMed Web of Science ®Google Scholar
• Kong D, Melo LG, Mangi AA et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation109(14), 1769–1775 (2004).
   PubMed Web of Science ®Google Scholar
• Werner N, Junk S, Laufs U et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res.93(2), E17–E24 (2003).
   PubMed Web of Science ®Google Scholar
• Kutryk MJ, Kuliszewski MA. In vivo endothelial progenitor cell seeding for the accelerated endothelialization of endovascular devices. Am. J. Cardiol.92(6), 94L (2003).
   Google Scholar
• Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J. Am. Coll. Cardiol.45(10), 1574–1579 (2005).
   PubMed Web of Science ®Google Scholar
• Duckers HJ, Silber S, de Winter RJ et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention3, 67–75 (2007).
   PubMedGoogle Scholar
• Duckers HJ, Soullie T, den Heijer P et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the HEALING II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroIntervention3, 350–358 (2007).
   PubMedGoogle Scholar
• Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest.105(1), 71–77 (2000).
   PubMed Web of Science ®Google Scholar
• Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood95(3), 952–958 (2000).
   PubMed Web of Science ®Google Scholar
• Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J. Am. Coll. Cardiol.51(6), 660–668 (2008).
   PubMed Web of Science ®Google Scholar
• Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res.89(1), E1–E7 (2001).
   PubMed Web of Science ®Google Scholar
• Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J. Am. Coll. Cardiol.45(9), 1441–1448 (2005).
   PubMed Web of Science ®Google Scholar
• Rauscher FM, Goldschmidt-Clermont PJ, Davis BH et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation108(4), 457–463 (2003).
   PubMed Web of Science ®Google Scholar
• Scheubel RJ, Zorn H, Silber RE et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol.42(12), 2073–2080 (2003).
   PubMed Web of Science ®Google Scholar
• Hoetzer GL, MacEneaney OJ, Irmiger HM et al. Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adults. Am. J. Cardiol.99(1), 46–48 (2007).
   PubMed Web of Science ®Google Scholar
• Ii M, Takenaka H, Asai J et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ. Res.98(5), 697–704 (2006).
   PubMed Web of Science ®Google Scholar
• Tepper OM, Galiano RD, Capla JM et al. Human endothelial progenitor cells from Type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation106(22), 2781–2786 (2002).
   PubMed Web of Science ®Google Scholar
• Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin. Sci. (Lond.)107(3), 273–280 (2004).
   PubMed Web of Science ®Google Scholar
• Michaud SE, Dussault S, Haddad P, Groleau J, Rivard A. Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis187(2), 423–432 (2006).
   PubMed Web of Science ®Google Scholar
• George J, Herz I, Goldstein E et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler. Thromb. Vasc. Biol.23(12), E57–E60 (2003).
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med.353(10), 999–1007 (2005).
   PubMed Web of Science ®Google Scholar
• Heeschen C, Lehmann R, Honold J et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation109(13), 1615–1622 (2004).
   PubMed Web of Science ®Google Scholar
• Massa M, Rosti V, Ferrario M et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood105(1), 199–206 (2005).
   PubMed Web of Science ®Google Scholar
• George J, Goldstein E, Abashidze S et al. Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur. Heart J.25(12), 1003–1008 (2004).
   PubMed Web of Science ®Google Scholar
• Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation103(23), 2776–2779 (2001).
   PubMed Web of Science ®Google Scholar
• Wojakowski W, Kucia M, Kazmierski M, Ratajczak MZ, Tendera M. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? Heart94(1), 27–33 (2008).
   PubMed Web of Science ®Google Scholar
• Laufs U, Werner N, Link A et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation109(2), 220–226 (2004).
   PubMed Web of Science ®Google Scholar
• Strehlow K, Werner N, Berweiler J et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation107(24), 3059–3065 (2003).
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest.108(3), 391–397 (2001).
   PubMed Web of Science ®Google Scholar
• Landmesser U, Engberding N, Bahlmann FH et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation110(14), 1933–1939 (2004).
   PubMed Web of Science ®Google Scholar
• Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation103(24), 2885–2890 (2001).
   PubMed Web of Science ®Google Scholar
• Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation105(25), 3017–3024 (2002).
   PubMed Web of Science ®Google Scholar
• Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood102(4), 1340–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Banerjee S, Brilakis E, Zhang S et al. Endothelial progenitor cell mobilization after percutaneous coronary intervention. Atherosclerosis189(1), 70–75 (2006).
   PubMed Web of Science ®Google Scholar
• Bonello L, Basire A, Sabatier F, Paganelli F, Dignat-George F. Endothelial injury induced by coronary angioplasty triggers mobilization of endothelial progenitor cells in patients with stable coronary artery disease. J. Thromb. Haemost.4(5), 979–981 (2006).
   PubMed Web of Science ®Google Scholar
• Garg R, Tellez A, Alviar C, Granada J, Kleiman NS, Lev EI. The effect of percutaneous coronary intervention on inflammatory response and endothelial progenitor cell recruitment. Catheter. Cardiovasc. Interv.72(2), 205–209 (2008).
   Google Scholar
• Kutryk MJ, Kuliszewski MA. In vivo endothelial progenitor seeding of stented arterial segments and vascular grafts. Circulation108(Suppl.), IV–573 (2003).
   Google Scholar
• Kutryk MJ, Kuliszewski MA. The future beyond drug eluting stents: endothelial cell capture. Int. Symp. Endovasc. Ther. Course Syllabus, 125–129 (2004).
   Google Scholar
• Duckers HJ, Soullie T, den Heijer P et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroIntervention3(3), 350–358 (2007).
   PubMedGoogle Scholar
• Miglionico M, Patti G, D’Ambrosio A, Di Sciascio G. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients. Catheter. Cardiovasc. Interv.71(5), 600–604 (2008).
   Google Scholar
• Co M, Tay E, Lee CH et al. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am. Heart J.155(1), 128–132 (2008).
   Google Scholar
• Cervinka P, Bystron M, Spacek R, Kvasnak M, Jakabcin J. Randomized comparison of Genous stent versus Chromium-Cobalt stent for treatment of ST elevation myocardial infarction. 6-month clinical angiographic and IVUS follow-up. Genius-STEMI trial. Presented at: American College of Cardiology I2 Summit 2009. Orlando, FL, USA, 28 March 2009.
   Google Scholar
• Kaul U, Bhatia V, Ghose T, Gupta R, Kachru R, Singh G. Angiographic follow-up of genous bioengineered stent in acute myocardial infarction (GENAMI) – a pilot study. Indian Heart J.60(6), 532–535 (2008).
   Google Scholar
• Tan HC. The use of endothelial progenitor cell capture stent in patients with ST-segment elevation myocardial infarction: 1-year clinical and angiographic outcomes. Presented at: China Interventional Therapeutics 2009. Beijing, China, 19 March 2009.
   Google Scholar
• de Winter RJ. The OrbusNeich GENOUS EPC-Capture stent clinical trial program; e-HEALING, AMC registry, TRIAS. Presented at: TCT 2008: Transcatheter Cardiovascular Therapeutics 20th Annual Scientific Symposium. Washington, DC, USA, 12–17 October 2008.
   Google Scholar
• Silber S. First results of the 1-year follow-up for the endothelial progenitor cells (EPC) capturing genous stent. Presented at: American Heart Association Scientific Sessions 2008. New Orleans, LA, USA, 8–12 November 2008.
   Google Scholar
• Assmus B, Urbich C, Aicher A et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res.92(9), 1049–1055 (2003).
   PubMed Web of Science ®Google Scholar
• Bustos C, Hernandez-Presa MA, Ortego M et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol.32(7), 2057–2064 (1998).
   PubMed Web of Science ®Google Scholar
• Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J. Clin. Invest.108(3), 399–405 (2001).
   PubMed Web of Science ®Google Scholar
• Duckers HJ, Onuma Y, Benit E et al. Final results of the HEALING 2B trial to evaluate a bioengineered CD34 antibody coated stent (Genous Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Presented at: American Heart Association Scientific Sessions 2008. New Orleans, LA, USA, 8–12 November 2008.
   Google Scholar
• de Winter RJ. The Genous pro-healing stent: plan for the best, insure against the worst. Presented at: Joint Interventional Meeting 2009. Rome, Italy, 12–14 February 2009.
   Google Scholar
• Klomp M, Beijk MA, Verouden C et al. One-year clinical outcome of a real world experience in patients treated with a GenousTM EPC capturing stent. Presented at: American Heart Association Scientific Sessions 2008. New Orleans, LA, USA, 8–12 November 2008.
   Google Scholar